Innovate UK is supporting eight innovative UK businesses to use digital, automated, and robotic technologies to optimise pharmaceutical process development and manufacturing.
These technologies will contribute to the vision of ‘labs of the future’ for medicines development and manufacturing, transitioning from traditional manual laboratory environments to highly efficient, intelligent, data driven laboratories.
Automation, robotics, artificial intelligence (AI), and connectivity will converge to accelerate research, development and manufacture of medicines, with the labs able to operate 24 hours a day, seven days a week.
Strengthening UK medicines manufacturing
The £9.3 million investment is through Innovate UK’s Transforming Medicines Manufacturing Innovation programme, part of UK Research and Innovation’s Industrial Strategy 8 Life Sciences programme.
The investment reflects Innovate UK’s commitment to helping innovative businesses develop and commercialise technologies that can strengthen UK competitiveness, boost productivity and support long-term economic growth.
Through the vision set out in its prospectus, Innovate UK is providing the funding, support and connections needed to help these businesses start, scale and stay in the UK.
Supporting diverse technologies
This portfolio spans a broad range of innovations across the life sciences and advanced manufacturing landscape, together supporting the creation of autonomous labs.
Technologies covered include next-generation smart platforms for radiopharmaceuticals, synthetic DNA production, as well as AI-enabled laboratories that accelerate the development and formulation of:
Funding is also supporting:
Combining expertise to improve outcomes
Hareklea Markides, Innovation Lead for Medicines Manufacturing at Innovate UK, said: “The Transforming Medicines Manufacturing Innovation programme demonstrates the incredible innovation taking place across the UK.
“By combining expertise in life sciences, advanced manufacturing and digital technologies, these businesses are developing solutions that could transform medicines development and manufacturing, further strengthening the UK’s global competitiveness.”
Winners:
Developing an automated laboratory, guided by causal artificial intelligence, that creates improved versions of existing medicines in a fraction of the usual time, using far less drug material.
Partner: Medicines Discovery Catapult
Building UK capability in radiopharmaceuticals by developing next-generation laboratory processes that future-proof how these promising medicines are made, strengthening domestic supply and improving patient access.
Partners: Cell and Gene Therapy Catapult, Lift Therapeutics, Microfluidx
Developing an automated lab where AI learns from live data to find the best way to manufacture cell-based cancer therapies, making medicines affordable.
Partner: Exmoor Pharma Concepts
Developing an AI-enabled system combining wearable technology and manufacturing data to support operators, improve quality, reduce production errors and make medicines manufacturing more efficient.
Building an end-to-end platform using AI and robotics to make pharmaceutical manufacturing faster and more efficient, enabling truly personalised medicine for patients at scale.
Developing an automated platform that designs and manufactures more patient-friendly medicines for improved cancer treatment.
Development and deployment of a telemetry-enabled synthetic DNA manufacturing platform, enabling faster, more reliable production of genetic medicines at the point of need.
Partners: Adthera Bio, Cell and Gene Therapy Catapult
Demonstrating a new decentralised model for cell and gene therapy manufacturing by combining automated production across a network of connected sites enabling widespread patient access.